Tackling Allogeneic Immunotherapy's Scale-Up Bottleneck With Vertical-Wheel® Bioreactors

While CAR T-cell therapies have shown success in treating blood cancers, they can come with severe side effects. Natural killer (NK) cells represent a safer, yet equally potent, option for immunotherapy, particularly for allogeneic applications. The main obstacle to their broader use is the difficulty of large-scale production. This paper details how PBS Biotech's Vertical-Wheel® Bioreactors address this critical issue. By providing a low-shear, homogenous environment, these bioreactors achieve superior cumulative fold expansion and cytotoxicity of NK cells compared to traditional static cultures, with performance improving at higher agitation rates.

To see a direct comparison and learn how to optimize your cell expansion process, download the complete application note.